Drug Search Results
More Filters [+]

Amitifadine

Alternative Names: amitifadine, eb-1010, eb1010, eb 1010
Latest Update: 2024-05-24
Latest Update Note: News Article

Product Description

a triple reuptake inhibitor of dopamine, norepinephrine and serotonin (Sourced from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7244379/)

Mechanisms of Action: DRI Inhibitor,SRI Inhibitor,NRI Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Nestle
Company Location: VEVEY V8
Company CEO:
Additonal Commercial Interests: Enterome

Clinical Description

Map of Global Clinical Trials for Amitifadine

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 3: Depressive Disorder, Major

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

SNRIs

P3

Completed

Depressive Disorder, Major

2013-02-01

Recent News Events